August 18, 2017 10:07 AM EDT
News Briefing

Medi­vir out-li­cens­es hep C drug to Chi­na’s As­cle­tis; Cel­lec­tis launch­es pi­o­neer­ing UCART123 US study

Shehla Shakoor

Managing Director

⇨ As­cle­tis has in-li­censed the Chi­nese mar­ket rights for Stock­holm-based Medi­vir’s NS5B in­hibitor for hep C. Terms weren’t dis­closed but Hangzhou-based As­cle­tis gets an­oth­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times